Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PRTO

Proteon Therapeutics (PRTO) Stock Price, News & Analysis

Proteon Therapeutics logo

About Proteon Therapeutics Stock (NASDAQ:PRTO)

Advanced Chart

Key Stats

Today's Range
$3.13
$3.32
50-Day Range
$0.84
$25.13
52-Week Range
$0.22
$3.94
Volume
101,859 shs
Average Volume
1.11 million shs
Market Capitalization
$69.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PRTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Proteon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PRTO Stock News Headlines

ProQR Therapeutics price target raised to $4 from $2.50 at Chardan
Protara Therapeutics (TARA) Earnings Dates & Reports
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
ProQR Therapeutics upgraded to Strong Buy from Outperform at Raymond James
ProQR Announces Major Share Offering Agreement
See More Headlines

PRTO Stock Analysis - Frequently Asked Questions

Proteon Therapeutics Inc (NASDAQ:PRTO) released its quarterly earnings data on Thursday, October, 31st. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.01.

Based on aggregate information from My MarketBeat watchlists, some other companies that Proteon Therapeutics investors own include Bristol Myers Squibb (BMY), SCYNEXIS (SCYX), Agile Therapeutics (AGRX), ImmunoGen (IMGN), Onconova Therapeutics (ONTX), Sierra Oncology (SRRA) and Tonix Pharmaceuticals (TNXP).

Company Calendar

Last Earnings
10/31/2019
Today
8/29/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:PRTO
CIK
1359931
Fax
N/A
Employees
17
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.15)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$20.73 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-118.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
5.98
Quick Ratio
5.98

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.06) per share
Price / Book
-52.33

Miscellaneous

Outstanding Shares
22,179,000
Free Float
N/A
Market Cap
$69.64 million
Optionable
Not Optionable
Beta
0.60
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:PRTO) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners